Accelerating enzyme optimization through an integrated design-to-function workflow
Tuesday, December 2, at 15:00 GMT | 16:00 CET | 10:00 EST | 7:00 PST
Ready to supercharge enzyme discovery? Join leaders from Ribbon Bio, Scala Biodesign, and Nuclera for an exclusive webinar on building a fully connected “Design–Build–Test–Learn” pipeline that propels protein engineering to new speeds and reliability.
Using a DNA-binding enzyme as a case study, this session will showcase how AI-driven protein design, advanced synthetic DNA assembly, and rapid expression technologies can converge to accelerate the discovery and validation of functional enzyme variants. Our expert speakers will guide you through each stage of the workflow, from target identification and in silico optimization, to DNA synthesis, expression screening, and functional evaluation of improved variants.
Discover how this integrated, cross-platform workflow not only slashes R&D timelines but also boosts your confidence in selecting winning variants while de-risking enzyme development projects.
Key learning objectives:
- Discover how AI-driven design can generate targeted enzyme variants optimized for activity, stability, or specificity.
- Accelerate the build phase with high-accuracy synthetic DNA, enabling rapid, seamless assembly of even complex or repetitive constructs.
- Streamline screening and scale-up with benchtop protein expression systems, bringing variant libraries from concept to testing faster than ever.
- Cut development timelines and reduce risk with a fully integrated “Design–Build–Test” workflow, taking your enzyme projects from gene to functional insight with confidence.
Who should attend?
- Scientists and engineers in enzyme engineering, synthetic biology, and biocatalysis
- R&D leaders in pharma, biotech, and industrial biotech exploring rapid protein optimization
- Researchers working on DNA-binding proteins, transcription factors, or enzyme characterization
- Business development and innovation managers seeking strategic technology collaborations in the design–make–test space
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Jodi brings over 18 years of experience leading high-performing commercial teams in the genomics market. She has a proven track record in building industry-leading organizations focused on operational efficiency and high-growth performance. As CEO of Ribbon Bio, she previously served as Chief Business Officer, where she built foundational commercial and product management infrastructure. Before joining Ribbon Bio, Jodi held executive roles at Agilent Technologies, overseeing global commercial operations and marketing for the Diagnostics and Genomics Divisions. She also led product management at Qiagen and field consulting for Roche Diagnostics’ OEM business. Jodi began her career as a bench scientist before moving into commercial leadership. She holds a degree in Molecular and Microbiology from Purdue University and conducted her master’s research in cancer biology.
Dr. Ravit Netzer is the Co-Founder and CEO of Scala Biodesign, a computational protein design startup that launched the ScalaOS platform. ScalaOS designs superior proteins with greater speed and accuracy, resulting in shorter time to market and higher success rates. Scala’s platform combines atomistic modelling, evolutionary data, and AI to create high-performance proteins in a single design round, introducing multiple beneficial mutations to enhance stability and activity without repeated cycles.
Michael Chen is the co-founder and CEO of Nuclera, a Cambridge (UK) and Boston (US) based life science tools company revolutionizing protein accessibility through the eProtein Discovery rapid protein access benchtop platform. With a mission to improve human health, Michael and his classmates founded Nuclera in response to the costly barriers to protein access for research and drug discovery. As CEO, he drives core inventions, sets the company's vision and strategy, and oversees its growth across two continents with over 100 employees. Before Nuclera, Michael was an award-winning structural biologist. His work resulted in numerous high-impact publications including Nature. Michael holds a BSc in Chemistry from the Georgia Institute of Technology and a PhD in Structural Biology/Chemistry from the University of Cambridge and the National Institutes of Health.
Moderator
